2011-10-12T16:22:33-05:00 2011-06-30 CLIFTON GUNDERSON LLP 1301 W 22ND ST STE 1100 OAK BROOK IL 60523 990 2010-07-01 731386920 GATEWAY FOR CANCER RESEARCH GATE 8473427450 1336 BASSWOOD ROAD SCHAUMBURG IL 60173 LYNETTE BISCONTI 5473427450 2011-10-07 1 GREGORY S ADAMS 6305738600 2010 2016-03-07 17:11:31Z LYNETTE BISCONTI 1336 BASSWOOD ROAD SCHAUMBURG IL 60173 2230266 0 X DEMANDCURESTODAY.ORG X 1991 OK CANCER STUDY AND RESEARCH 15 14 0 0 0 0 2161499 1891889 0 0 15754 19924 1325287 32010 3502540 1943823 475573 876183 0 0 0 0 0 0 0 211418 204955 686991 1081138 2815549 862685 3855562 4932304 1414011 1628068 2441551 3304236 X TO FUND INNOVATIVE AND LIFE-CHANGING CLINICAL STUDIES THAT ACCELERATE NEW TREATMENT OPTIONS FOR CANCER PATIENTS. 0 0 1068812 876183 GATEWAY FOR CANCER RESEARCH (FORMERLY KNOWN AS CANCER TREATMENT RESEARCH FOUNDATION OR CTRF), A NON-PROFIT 501(C)(3) ORGANIZATION, WAS ESTABLISHED IN 1991 TO PROMOTE RESEARCH THROUGH THE TREATMENT PROCESS AND SUPPORT PROGRESSIVE MOLECULAR, NUTRITIONAL AND IMMUNOLOGICAL RESEARCH PROGRAMS THAT MORE TRADITIONAL CANCER RESEARCH INSTITUTIONS MAY NOT FUND. GATEWAY IS DEDICATED TO ADVANCING INNOVATIONS IN THE SCIENTIFIC COMMUNITY AND SPEEDING THEM TO THE CANCER PATIENT'S BEDSIDE. THE WORK OF GATEWAY IS ABOUT GIVING CANCER PATIENTS THE ABILITY TO LIVE LONGER, MORE FULFILLING AND HEALTHIER LIVES.NO PORTION OF ANY PUBLIC CONTRIBUTION TO GATEWAY GOES TO FUNDRAISING OR ADMINISTRATIVE SALARIES. DUE TO GENEROUS CORPORATE UNDERWRITING OF ADMINISTRATIVE EXPENSES, 99% OF PUBLIC CONTRIBUTIONS RECEIVED ARE APPLIED DIRECTLY TO SUPPORT AGGRESSIVE CANCER RESEARCH AND SCIENTIFIC DEVELOPMENT PROGRAMS. OUR SCIENTIFIC BOARD APPLIES STRINGENT GUIDELINES FOR REVIEWING EACH GRANT APPLICATION, RECOMMENDING TO THE BOARD OF DIRECTORS ONLY THOSE THAT ARE IN KEEPING WITH THE FOUNDATION'S MISSION. THROUGH THIS FORMAL REVIEW PROCESS, GATEWAY ENSURES THAT FUNDING IS GRANTED STRICTLY TO THOSE PROJECTS THAT ARE TRULY INNOVATIVE AND HAVE THE POTENTIAL TO QUICKLY TRANSLATE FROM THE RESEARCHER'S LABORATORY TO THE PATIENT'S BEDSIDE.AS THE NATION'S SECOND MOST DEADLY AND COSTLY DISEASE, CANCER RECOGNIZES NO BOUNDARIES. IN THE BATTLE AGAINST CANCER, GATEWAY IS ON THE FRONTLINES, SUPPORTING CLINICAL RESEARCH INITIATIVES DESIGNED TO ENHANCE QUALITY OF LIFE FOR CANCER PATIENTS, SURVIVORS, AND FAMILIES IN EVERY COMMUNITY NATIONWIDE. GATEWAY FOR CANCER RESEARCH HAS FUNDED, OR IS CURRENTLY FUNDING, 112 INNOVATIVE RESEARCH PROJECTS DEALING WITH NEW AGENT STUDIES, IMMUNOLOGY, NUTRITION, AND GENE THERAPY. COMPARED TO OTHER ORGANIZTIONS OF OUR SIZE, WE ARE CLEARLY AMONG THE MOST SUCCESSFUL OF CANCER RESEARCH FOUNDATIONS. THE QUALITY OF OUR FUNDED RESEARCH CONTINUES TO IMPROVE EVERY YEAR AS WE RELENTLESSLY PURSUE THE MOST EXCITING PROSPECTS FOR CUTTING EDGE CLINICAL RESEARCH WITH IMPORTANT PATIENT IMPACT.BECAUSE WE ARE VIGILANT ABOUT MONITORING OUR CLINICAL RESEARCH STUDIES, WE CAN ASSURE OUR FUNDING PARTNERS THE BEST UTILIZATION OF THEIR CONTRIBUTIONS. WE IDENTIFY AND ENCOURAGE GREATER INTERACTION WITH OUR BEST RESEARCHERS AND ENCOURAGE APPLICATIONS FROM CLINICAL INVESTIGATORS WHO CONSISTENTLY PROVIDE US WITH IMPORTANT PATIENT IMPACT RESEARCH.HISTORICAL DOCUMENTATION OF OUR RESEARCH PROJECTS PROVIDES A WINDOW THROUGH WHICH WE CAN VIEW OUR PAST ACCOMPLISHMENTS AND IMPLEMENT NEW STRATEGIC PROGRAMS THAT REFLECT OUR MISSION - TO FUND INNOVATIVE AND LIFE-CHANGING CLINICAL STUDIES THAT ACCELERATE NEW TREATMENT OPTIONS FOR CANCER PATIENTS. 1068812 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 1 10 0 0 0 0 0 0 0 1 1 0 0 0 0 X 15 14 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 AZ CA CO CT FL IL ME MD MA MI MN MT MO NH NJ NY NC OH OK PA RI SC TN TX VA WA WI X X MR IRWIN FONG 8473427450 1336 BASSWOOD ROAD SCHAUMBURG IL 60173 X SUSAN REILLEY 0.30 X 0 0 0 LYNETTE BISCONTI 30.00 X X 0 0 0 WAYNE DIXON 0.30 X X 0 0 0 DOTTIE RZESZUTKO 0.30 X X 0 0 0 KENNETH SMITH 0.30 X X 0 0 0 CONNIE PAYTON 0.30 X 0 0 0 JOSEPH A GREGOIRE 0.30 X 0 0 0 BRUCE LUBIN 0.30 X 0 0 0 ROBERT W MAYO 0.30 X 0 0 0 ROD A MURRAY 0.30 X 0 0 0 THOMAS R DUENSING 0.30 X 0 0 0 MICHAEL MULLINS 0.30 X X 0 0 0 RICHARD J STEPHENSON 0.30 X X 0 0 0 HARLAN TELLER 0.30 X 0 0 0 RHONDA KOKUT 0.30 X 0 0 0 0 0 0 0 0 0 0 PALMER HOUSE HILTON 17 E MONROE STREET CHICAGO IL 60603 GALA EVENT FACILITY SERVICES 136262 1 49496 1494455 347938 300033 1891889 19924 19924 286443 1494455 286443 0 RETURN OF UNUSED GRANT 900099 32010 32010 32010 1943823 32010 0 19924 876183 876183 SCIENTIFIC DEVELOPMENT 150000 150000 BOARD OF SCIENTIFIC COU 42000 42000 MISCELLANEOUS 12955 629 12326 1081138 1068812 12326 0 776629 165410 2834908 4707915 222890 45519 12785 5110 8350 8350 3855562 4932304 113 1413898 1628068 1414011 1628068 X 1617101 2526816 824450 777420 2441551 3304236 3855562 4932304 862685 0 X X 0 1 1 X 0 X 2368215 2138067 2050754 2161499 1891889 10610424 2368215 2138067 2050754 2161499 1891889 10610424 1021002 9589422 94251 89540 31109 15754 19924 250578 10861002 8258633 0.88290 0.88590 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1943823 1081138 862685 0 862685 3676715 1446449 286443 1732892 1943823 0 1943823 2814030 1446449 286443 1732892 1081138 0 1081138 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X: THE FOUNDATION EVALUATES ITS EXPOSURE FOR UNCERTAIN TAX POSITIONS ON AN ANNUAL BASIS. AS OF JUNE 30, 2011 AND 2010, THERE WERE NO LIABILITIES RELATED TO UNCERTAIN TAX POSITIONS. THE FEDERAL AND STATE RETURNS OF THE FOUNDATION FOR TAX YEARS 2007, 2008, AND 2009 ARE SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE AND STATE TAXING AUTHORITIES, GENERALLY FOR THREE YEARS AFTER THEY WERE FILED. SCHEDULE D, PARTS XII AND XIII, LINES 2D - AMOUNTS REPRESENT DIRECT EXPENSES FOR SPECIAL EVENTS HELD AND ARE REFLECTED IN PART VIII ON LINE 8B AGAINST REVENUES FROM FUNDRAISING EVENTS. GALA FUNDRAISER 1780898 1494455 286443 136262 150181 0 1780898 1494455 286443 136262 150181 286443 0 1 MEMORIAL SLOAN-KETTERING CANCER CENTERWESA 1275 YORK AVENUE BOX 701 NEW YORK NY 10065 131924236 501(C)(3) 299136 CANCER RESEARCH MEMORIAL SLOAN-KETTERING CANCER CENTERSCHWARTZ 1275 YORK AVENUE BOX 701 NEW YORK NY 10065 131924236 501(C)(3) 466528 CANCER RESEARCH UCSFCOHEN 3333 CALIFORNIA STREET STE 340 SAN FRANCISCO CA 94118 946036493 170(B)(1)(A)II 110519 CANCER RESEARCH 3 0 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: ALL GRANT APPLICATIONS MUST GO THROUGH A RIGOROUS PEER REVIEW PROCESS LED BY OUR BOARD OF SCIENTIFIC COUNSELORS - A DISTINGUISHED BOARD OF RENOWNED SCIENTISTS, PHYSICIANS, AND RESEARCHERS. THROUGH THIS PROCESS, SCIENTISTS INCLUDING EXPERTS IN A PARTICULAR AREA OF CANCER REVIEW AND EVALUATE APPLICATIONS AGAINST A CAREFULLY PRESCRIBED SET OF CRITERIA FOR JUDGING THE SCIENTIFIC MERIT AND POTENTIAL VALUE OF EACH PROPOSED STUDY. THIS REVIEW, NOT ONLY INCLUDES A NUMERICAL GRADING OF OBJECTIVE CRITERIA BUT ALSO, INCLUDES A SUBJECTIVE COMMENTARY WITH SUGGESTED MODIFICATIONS. UPON RECOMMENDATION BY THE BOARD OF SCIENTIFIC COUNSELORS, THE APPLICATION IS SUBMITTED TO GATEWAY'S BOARD OF DIRECTORS FOR FUNDING CONSIDERATION. THE STRINGENT REVIEW PROCESS, DESCRIBED ABOVE, IS CONTINUED DURING THE COURSE OF THE STUDY, IF APPROVED AND FUNDED, WHEN REQUIRED PROGRESS REPORTS ARE SUBMITTED. THE PROGRESS REPORTS ARE REVIEWED BY THE BOARD OF SCIENTIFIC COUNSELORS AND RECOMMENDATIONS AND MODIFICATIONS ARE MADE, IF DEEMED NECESSARY, BY THE BOARD PRIOR TO PAYMENT OF ADDITIONAL FUNDS. BRUCE LUBIN CURRENT DIRECTOR OF GATEWAY FOR CANCER RESEARCH 4707267 MR. LUBIN IS AN OFFICER OF THE PRIVATEBANK AND TRUST CO. WHICH HOLDS CASH AND SHORT-TERM INVESTMENTS OF THE ORGANIZATION. 0 X 1 147712 QUOTED PRICE ON EXCHANGE X AUCTION DONATIONS (TRAVEL & ENTERTAINMENT) 39 49697 SELLING PRICE OF DONATED PROPERTY X AUCTION DONATIONS (SPORTS ITEMS) 52 28954 EXPERT OPINION OF VALUE X AUCTION DONATIONS (ELECTRONICS) 9 2644 SELLING PRICE OF DONATED PROPERTY X AUCTION DONATIONS (PERSONAL ITEMS) 188 71026 SELLING PRICE OF DONATED PROPERTY 0 0 0 FORM 990, PART VI, SECTION B, LINE 11 FORM 990 IS FIRST REVIEWED BY THE ORGANIZATION'S INTERNAL STAFF AND A SUBSEQUENT REVIEW BY EXECUTIVE STAFF. THE FORM 990 IS THEN REVIEWED BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS AND SENT TO EACH CURRENT MEMBER OF THE BOARD FOR THEIR REVIEW AND ACTION. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S BOARD MEMBERS AND STAFF ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY DURING A REGULARLY SCHEDULED BOARD MEETING AND DURING THE STAFF MEMBERS ANNUAL PERFORMANCE EVALUATION MEETING. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC VIA IT'S WEBSITE AND OTHER NONPROFIT PUBLICATIONS. FORM 990, PART XII, LINE 2C: AN AUDIT COMMITTEE PROVIDES OVERSIGHT TO THE FOUNDATION'S ANNUAL AUDIT. THIS PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. FOUNDATION ADMINISTRATIVE COST SUPPORT: MOST OF THE FOUNDATION'S ADMINISTRATIVE COSTS ARE PAID FOR BY THE CANCER TREATMENT CENTERS OF AMERICA, AN ILLINOIS CORPORATION, UNDER AN ADMINISTRATIVE SPONSORSHIP ARRANGEMENT. THIS ARRANGEMENT ALLOWS THE FOUNDATION TO FOCUS ALL OF ITS EFFORTS ON ITS MISSION OF FUNDING INNOVATIVE PATIENT-CENTERED CANCER RESEARCH. CONSEQUENTLY, APPROXIMATELY 99% OF ALL DONATIONS TO THE FOUNDATION CAN BE DIRECTED TO FUND INNOVATIVE AND LIFE-CHANGING CLINICAL STUDIES THAT ACCELERATE NEW TREATMENT OPTIONS FOR CANCER PATIENTS. THESE ADMINISTRATIVE COSTS INCLUDE SALARIES AND BENEFITS, OCCUPANCY RELATED EXPENSES, PROFESSIONAL FEES AND OTHER OPERATING EXPENSES SUCH AS TRAVEL, ADVERTISING AND MARKETING, REPAIR AND MAINTENANCE, AND IT RELATED COSTS.